http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2740913-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b78c620d1d3cadeaae214bffb2de6b5 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1729 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-18 |
| filingDate | 2017-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60c2dc0f85106fae4ea27c11317daaf7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf8693a5182774cb642ee4284de282f0 |
| publicationDate | 2021-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2740913-C2 |
| titleOfInvention | Treatment of liver, bile duct and pancreatic disorders |
| abstract | FIELD: medicine. n SUBSTANCE: group of inventions relates to methods of treating or preventing disorders of the liver, bile ducts and pancreas. A method of treating or preventing a liver disease or disorder selected from a group consisting of toxic liver damage, alcoholic or non-alcoholic fatty liver disease (NAFLD), hepatic cirrhosis, hepatic insufficiency, hepatic fibrosis, liver sclerosis, hepatic encephalopathy, non-alcoholic steatohepatitis (NASH), wherein said method comprises administering an effective amount of α-defensin and/or β-defensin of mammals selected from a group consisting of hBD-2 (SEQ ID NO: 5), truncated hBD2 (SEQ ID NO: 17), hBD-1 (SEQ ID NO: 4), hBD-3 (SEQ ID NO: 6), and hBD-4 (SEQ ID NO: 7), β-defensin, which differs from hBD1, hBD2, hBD3, hBD4, or truncated hBD2 (SEQ ID NO: 17) by less than 5 conserved amino acid substitutions, HD5 (SEQ ID NO: 8), and/or HD6 (SEQ ID NO: 9), a subject in need thereof. Also disclosed are a method of treating or preventing a biliary disease or disorder, a method of treating or preventing a disease or a pancreatic disorder, method of treating or preventing a metabolic disease or disorder, using α-defensin and/or β-defensin in mammals in a method of treating and preparing a medicinal agent. n EFFECT: treatment of liver, bile duct and pancreatic disorders is offered. n 35 cl, 38 dwg, 10 ex |
| priorityDate | 2016-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 325.